Benchmarking Care in Psoriatic Arthritis - The QUANTUM Report: A Report from the GRAPPA 2016 Annual Meeting

Guillaume Favier^{1

2}, Dafna D Gladman^{1

2}, Joseph F Merola^{1

2}, April W Armstrong^{1

2}, Wolf Henning Boehncke^{1

2}, Philip S Helliwell^{3

4}

Affiliations

¹ From the Strategy Group, Healthcare and Life Sciences, KPMG LLP ( UK), London; University of Leeds, Leeds; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Dermatology and Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; University of Southern California, Los Angeles, California, USA; Division of Dermatology, Geneva University Hospital; Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
² G. Favier, PhD, Manager, Strategy Group, Healthcare and Life Sciences, KPMG LLP ( UK); D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Disease Program, Toronto Western Hospital; J.F. Merola, MD, MMSc, Assistant Professor, Department of Dermatology and Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School; A.W. Armstrong, MD, University of Southern California; W.H. Boehncke, MD, Division of Dermatology, Geneva University Hospital, and Department of Pathology and Immunology, University of Geneva; P.S. Helliwell, DM, PhD, FRCP, University of Leeds, and Bradford Hospitals NHS Foundation Trust.
³ From the Strategy Group, Healthcare and Life Sciences, KPMG LLP ( UK), London; University of Leeds, Leeds; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Dermatology and Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; University of Southern California, Los Angeles, California, USA; Division of Dermatology, Geneva University Hospital; Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland. p.helliwell@leeds.ac.uk.
⁴ G. Favier, PhD, Manager, Strategy Group, Healthcare and Life Sciences, KPMG LLP ( UK); D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Disease Program, Toronto Western Hospital; J.F. Merola, MD, MMSc, Assistant Professor, Department of Dermatology and Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School; A.W. Armstrong, MD, University of Southern California; W.H. Boehncke, MD, Division of Dermatology, Geneva University Hospital, and Department of Pathology and Immunology, University of Geneva; P.S. Helliwell, DM, PhD, FRCP, University of Leeds, and Bradford Hospitals NHS Foundation Trust. p.helliwell@leeds.ac.uk.

PMID: 28461523
DOI: 10.3899/jrheum.170142

Benchmarking Care in Psoriatic Arthritis - The QUANTUM Report: A Report from the GRAPPA 2016 Annual Meeting

Guillaume Favier et al. J Rheumatol. 2017 May.

. 2017 May;44(5):674-678.

doi: 10.3899/jrheum.170142.

Authors

Guillaume Favier^{1

2}, Dafna D Gladman^{1

2}, Joseph F Merola^{1

2}, April W Armstrong^{1

2}, Wolf Henning Boehncke^{1

2}, Philip S Helliwell^{3

4}

Affiliations

¹ From the Strategy Group, Healthcare and Life Sciences, KPMG LLP ( UK), London; University of Leeds, Leeds; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Dermatology and Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; University of Southern California, Los Angeles, California, USA; Division of Dermatology, Geneva University Hospital; Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
² G. Favier, PhD, Manager, Strategy Group, Healthcare and Life Sciences, KPMG LLP ( UK); D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Disease Program, Toronto Western Hospital; J.F. Merola, MD, MMSc, Assistant Professor, Department of Dermatology and Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School; A.W. Armstrong, MD, University of Southern California; W.H. Boehncke, MD, Division of Dermatology, Geneva University Hospital, and Department of Pathology and Immunology, University of Geneva; P.S. Helliwell, DM, PhD, FRCP, University of Leeds, and Bradford Hospitals NHS Foundation Trust.
³ From the Strategy Group, Healthcare and Life Sciences, KPMG LLP ( UK), London; University of Leeds, Leeds; Bradford Hospitals UK National Health Service (NHS) Foundation Trust, Bradford, UK; University of Toronto; Krembil Research Institute; Psoriatic Disease Program, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Dermatology and Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; University of Southern California, Los Angeles, California, USA; Division of Dermatology, Geneva University Hospital; Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland. p.helliwell@leeds.ac.uk.
⁴ G. Favier, PhD, Manager, Strategy Group, Healthcare and Life Sciences, KPMG LLP ( UK); D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Disease Program, Toronto Western Hospital; J.F. Merola, MD, MMSc, Assistant Professor, Department of Dermatology and Medicine, Division of Rheumatology, Brigham and Women's Hospital, Harvard Medical School; A.W. Armstrong, MD, University of Southern California; W.H. Boehncke, MD, Division of Dermatology, Geneva University Hospital, and Department of Pathology and Immunology, University of Geneva; P.S. Helliwell, DM, PhD, FRCP, University of Leeds, and Bradford Hospitals NHS Foundation Trust. p.helliwell@leeds.ac.uk.

PMID: 28461523
DOI: 10.3899/jrheum.170142

Abstract

Members of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), in partnership with KPMG LLP (UK), conducted interviews at selected research centers around the globe to analyze the process of care in psoriasis and psoriatic arthritis (PsA): pre-diagnosis, referral and diagnosis, treatment, and followup. Ten major challenges emerged, many of which were universally recognized across centers; the top 4 included limited awareness of PsA among non-rheumatologists, a disparate approach to care, late referral and diagnosis, and an inadequate management of comorbidities.

Keywords: GRAPPA; OUTCOMES; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF CARE.

PubMed Disclaimer

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- HighWire
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Benchmarking Care in Psoriatic Arthritis - The QUANTUM Report: A Report from the GRAPPA 2016 Annual Meeting

Affiliations

Benchmarking Care in Psoriatic Arthritis - The QUANTUM Report: A Report from the GRAPPA 2016 Annual Meeting

Authors

Affiliations

Abstract

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Research Materials

Miscellaneous